Page 2,698«..1020..2,6972,6982,6992,700..2,7102,720..»

Research and Markets: Stem Cell Research in India 2012

Posted: July 11, 2012 at 6:14 pm

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/t2whtl/stem_cell_research) has announced the addition of the "Stem Cell Research in India 2012" report to their offering.

The stem cell research in India is in its nascent stage and is gradually on a growth path of acceptance by people. The market is still in a phase of conducting research to establish itself as one of the best therapies for the widely prevalent incurable lifestyle diseases. Awareness campaigns and doctors are playing a key role educating people and especially would-be parents about the benefits associated with preserving stem cells.

The report begins with the introduction section which offers a brief insight of the concept of stem cell therapy and banking, the conventional sources of stem cells and the current and future therapeutic solutions for the most risky diseases. It then moves to the market overview section which provides an insight of the Indian stem cell therapy market, with highlight on the market size and growth. It also covers the market size and growth prospect of the stem cell banking market in India. In addition to these, the report gives a snapshot of the current and expected stem cell banking customers.

An analysis of the drivers explains the factors for growth of the industry that include favourable regulatory environment, high patient population, stem cell application in drug development, rising consumer awareness, a rise in medical tourism and an increase in research and development expenditure to ensure stem cell therapy as a viable treatment for the numerous diseases. The key challenges include high cost of therapy, capital intensive market and high development costs of stem cell resulting in slow progress of the market.

Companies Mentioned

- Cyrobanks International India Private Limited

- LifeCell International Private Limited

- Pathcare Labs (P) Limited

- Reliance Life Sciences Private Limited

Read the original here:
Research and Markets: Stem Cell Research in India 2012

Posted in Stem Cell Research | Comments Off on Research and Markets: Stem Cell Research in India 2012

Cord Blood Stem Cells Restore Toddler’s Hearing

Posted: July 11, 2012 at 4:13 pm

A virus infection Stephanie Connor acquired during pregnancy put her unborn daughter at significant risk for brain damage and lifelong hearing loss.

"It was traumatic," said Connor, of LaBelle, Fl, after learning about her daughter's condition. "It was like mourning the loss of a child."

At age 1, baby Madeleine was completely deaf in her right ear and her hearing was severely lost in the left, said Connor. While a hearing aid helped to amplify some sounds for Madeleine, it would never fully repair the damage in her ear.

But a simple experimental procedure that Connor enrolled in for Madeleine may have restored her hearing and reversed her condition.

In January 2012, Madeleine, 2, became the first child to undergo an experimental hearing loss treatment through an FDA-approved trial at Memorial Hermann-Texas Medical Center that infused stem cells from her own banked cord blood into her damaged inner ear.

Within the last six months, Connor says she's seen a dramatic improvement in Madeleine's ability to hear.

"Before, when she would hear something she would look all around," Connor said. "But now we notice that she turns in the right direction of the sound."

Madeleine was also able to speak for the first time, Connor said.

For more than two decades, umbilical cord blood transplantation -- either by a baby's own cord blood or another's, depending on the type of procedure -- has been used to treat otherwise fatal diseases including blood disorders, immune diseases, and some types of cancers.

Infusing cord blood stem cells into the body may also have the potential to heal and regenerate damaged cells and tissues.

Continued here:
Cord Blood Stem Cells Restore Toddler's Hearing

Posted in Stem Cells | Comments Off on Cord Blood Stem Cells Restore Toddler’s Hearing

Stem Cells Restore Toddler’s Hearing

Posted: July 11, 2012 at 4:13 pm

A virus infection Stephanie Connor acquired during pregnancy put her unborn daughter at significant risk for brain damage and lifelong hearing loss.

"It was traumatic," said Connor, of LaBelle, Fl, after learning about her daughter's condition. "It was like mourning the loss of a child."

At age 1, baby Madeleine was completely deaf in her right ear and her hearing was severely lost in the left, said Connor. While a hearing aid helped to amplify some sounds for Madeleine, it would never fully repair the damage in her ear.

But a simple experimental procedure that Connor enrolled in for Madeleine may have restored her hearing and reversed her condition.

In January 2012, Madeleine, 2, became the first child to undergo an experimental hearing loss treatment through an FDA-approved trial at Memorial Hermann-Texas Medical Center that infused stem cells from her own banked cord blood into her damaged inner ear.

Within the last six months, Connor says she's seen a dramatic improvement in Madeleine's ability to hear.

"Before, when she would hear something she would look all around," Connor said. "But now we notice that she turns in the right direction of the sound."

Madeleine was also able to speak for the first time, Connor said.

For more than two decades, umbilical cord blood transplantation -- either by a baby's own cord blood or another's, depending on the type of procedure -- has been used to treat otherwise fatal diseases including blood disorders, immune diseases, and some types of cancers.

Courtesy Stephanie Connor

Continued here:
Stem Cells Restore Toddler's Hearing

Posted in Stem Cells | Comments Off on Stem Cells Restore Toddler’s Hearing

Malayan Tiger and Black Leopard Undergo Treatment for Arthritis Using Stem Cells Prepared by InGeneron Incorporated

Posted: July 11, 2012 at 9:14 am

Houston, TX (PRWEB) July 11, 2012

InGeneron Incorporated and Gulf Coast Veterinary Surgery (GCVS) teamed up with The Houston Zoo to help two of the zoos popular cats on June 20, 2012. Pandu, a 286-pound Malayan tiger, and Ivy, a 68-pound black leopard, suffer from arthritic pain. Zoo veterinarians Dr. Lauren Howard and Dr. Maud Marin have extensive experience with surgical procedures on the zoos animals, but these were unusually complicated cases. Therefore, the Houston Zoo called Dr. Brian Beale of Gulf Coast Veterinary Surgery to provide surgical expertise, and InGeneron Incorporated to provide the latest products enabling autologous stem cell therapy for osteoarthritis.

Dr. Beale and Dr. Howard harvested a small amount of fat tissue from the abdomen of each of the animals and then processed using InGenerons ARC System to isolate the stem cells. While the tissue from each animal was being processed, Dr. Beale performed arthroscopic surgery of the damaged elbow on each animal to evaluate and treat the cause of the arthritis. Arthroscopy is a minimally-invasive surgical technique that allows increased surgical precision and rapid patient recovery.

Dr. Carl Friddle of InGeneron Incorporated said, "Once the fat was removed, we cut it into small pieces before processing. This helps our proprietary enzyme mix gently remove the cells from the fat tissue." With InGenerons ARC System the veterinarian can rapidly isolate and concentrate the abundance of regenerative cells found in adipose (fat) tissue so that they can be administered in a single procedure without the need to grow the cells for several weeks. This enables veterinarians to use regenerative cell therapy in their clinics, or at remote locations, to treat orthopedic injuries, degenerative conditions and non-healing wounds in companion and performance animals.

With our process, we yield a high percentage of live regenerative cells, and systematic studies have shown these adipose-derived regenerative cells secrete growth factors that induce healing and formation of new blood vessels, elicit potent anti-inflammatory effects and have the great potential to engraft and differentiate into specialized cells to restore function to the tissue where they are administered, said Dr. Michael Coleman, President and Chief Scientific Officer of InGeneron Incorporated.

Veterinarians are hopeful that the new cell therapy will shorten the healing time and provide a better, longer lasting result.

Dr. Beale showed the degeneration in Pandu's elbow to the treatment collaborators on the operating room video monitor. In some areas of the damaged joint, there was bone on bone contact, and bone fragments had broken loose. "This is by far the largest fragment I've ever seen with this condition," said Dr. Beale, who often performs this same procedure on house cats and dogs. Ivy had similar changes to Pandu but in both elbows.

Thanks to InGenerons rapid method for cell isolation, Pandu and Ivy both had their own regenerative cells ready for injection by the end of their surgeries. Dr. Beale injected the cells into the affected elbow in only a couple of minutes, and both cats were taken back to familiar surroundings for rest and recuperation. Neither animal showed any complications from the surgery and within a week both were back on exhibit.

Veterinarians in the USA, Canada, Europe, and Mexico are currently using InGenerons ARC System. Last year, InGeneron collaborated with Dr. Francisco Cortes Van Aarem in Mexico to provide regenerative cell therapy to Tibetana, a rescued Bengal tiger, with serious injuries to her back. Today, Tibetana is doing well at the Zacango Zoo.

A wide range of injured animals, including household pets and performance animals, may benefit from this innovative type of procedure.

Read more here:
Malayan Tiger and Black Leopard Undergo Treatment for Arthritis Using Stem Cells Prepared by InGeneron Incorporated

Posted in Stem Cell Videos | Comments Off on Malayan Tiger and Black Leopard Undergo Treatment for Arthritis Using Stem Cells Prepared by InGeneron Incorporated

GEN reports on growth of tissue engineering revenues

Posted: July 11, 2012 at 3:20 am

Public release date: 10-Jul-2012 [ | E-mail | Share ]

Contact: John Sterling jsterling@genengnews.com 914-740-2196 Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, July 9, 2012More than half (52%) of the companies comprising the tissue engineering (TE) and stem cell industries are revenue-generating, compared to about 21% four years ago, reports Genetic Engineering & Biotechnology News (GEN). Of those companies, 31% have commercial products and 21% are service-based; another 30% have products in clinical trials, according to the current issue of GEN.

The GEN article is based on interviews with leading tissue engineering researchers and on the findings of a landmark paper ("Progress in the Tissue Engineering and Stem Cell Industry, Are we there yet"), which appears in Tissue Engineering: Part B, Volume 18, Number 3, 2012, published by Mary Ann Liebert, Inc.

"Like many other biotechnologies, tissue engineering has experienced an up and down history," said John Sterling, Editor in Chief of GEN. "But with numerous technical advances moving the field forward combined now with rising revenues, this segment of bioresearch is really taking off."

The industry itself is beginning to attain profitability, with sales revenues reaching $3.5 billion and industry spending approaching $3.6 billion. The 2012 analysis by a group led by Robert Langer, Sc.D., one of the authors of the paper in the Liebert journal, reported a nearly threefold increase in commercial sales for TE and stem cell products and services compared to the previous four-year period. Furthermore, the number of companies selling products or offering services increased more than twofold to 106.

The GEN article also notes that Tissue Engineering has formed an industry council for the purpose of helping to guide the evolution of the industry and to create strategic initiatives aimed at overcoming some of the R&D, manufacturing, and regulatory challenges facing the industry.

Among the companies interviewed for the GEN article are Organogenesis, Cytograft Tissue Engineering, Scintellix, and Humacyte.

###

For a copy of the July issue of GEN, please call (914) 740-2146, or email: pbartell@genengnews.com

Read more:
GEN reports on growth of tissue engineering revenues

Posted in Genetic Engineering | Comments Off on GEN reports on growth of tissue engineering revenues

Bibiyahe sa Germany kasama si Ruffa, Annabelle magpapakondisyon sa kampanya kaya magpapa-stem cell therapy

Posted: July 11, 2012 at 3:19 am

Tuloy na ang stem cell therapy ni Annabelle Rama dahil naka-schedule na siyang pumunta sa Germany sa first week ng September.

Kasama ni Annabelle sa Germany trip ang kanyang anak na si Ruffa Gutierrez. Hindi ako sure kung may plano rin si Ruffa na magpa-stem cell therapy dahil walang age limit ang procedure na pinag-uusapan na ngayon sa apat na sulok ng showbiz.

Tinutukso si Annabelle Rama na may kinalaman sa kanyang pagkandidato sa Cebu ang desisyon niya na sumailalim sa stem cell therapy.

Tumawa lang si Bisaya na mukhang seryoso na sa pagkandidato bilang kongresista ng North Cebu sa eleksiyon sa susunod na taon.

Binibiro si Bisaya na magpapa-stem cell therapy siya para kundisyon na kundisyon ang katawan niya habang nangangampanya sa North Cebu.

Ayaw kumpirmahin ni Bisaya ang political plans niya. Hintayin na lamang daw ng mga tao ang kanyang bonggang announcement sa October.

Asawa ni Jose nag-iba ng abogado matapos matalo

How true na iba na raw ang lawyers ni Analyn Manalo kaya tumanggi nang magsalita ang kanyang mga dating abogado?

Si Analyn ang kontrobersiyal na dyowa ni Jose Manalo. Ilang buwan nang nasa news ang mag-asawa dahil sa kanilang paghihiwalay.

News noong weekend na natalo si Analyn sa kaso na isinampa niya laban kay Jose.

See more here:
Bibiyahe sa Germany kasama si Ruffa, Annabelle magpapakondisyon sa kampanya kaya magpapa-stem cell therapy

Posted in Stem Cell Therapy | Comments Off on Bibiyahe sa Germany kasama si Ruffa, Annabelle magpapakondisyon sa kampanya kaya magpapa-stem cell therapy

NeoStem to Present at the Seventh Annual JMP Securities Healthcare Conference

Posted: July 11, 2012 at 1:10 am

NEW YORK, July 10, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a cell therapy company, today announced that its CEO will present at the Seventh Annual JMP Securities Healthcare Conference on July 12, 2012.

The presentation will be webcast live and available to view at the following web address: http://wsw.com/webcast/jmp18/nbs/. The webcast will be archived for 90 days following the live presentation.

The Seventh Annual JMP Securities Healthcare Conference

About NeoStem, Inc.

NeoStem, Inc. ("we," "NeoStem" or the "Company") continues to develop and build on its core capabilities in cell therapy to capitalize on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a large role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. Our January 2011 acquisition of Progenitor Cell Therapy, LLC ("PCT") provides NeoStem with a foundation in both manufacturing and regulatory affairs expertise. We believe this expertise, coupled with our existing research capabilities and collaborations, will allow us to achieve our mission of becoming a premier cell therapy company. Our PCT subsidiary's manufacturing base is one of the few current Good Manufacturing Practices ("cGMP") facilities available for contracting in the burgeoning cell therapy industry. Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR-001, represents NeoStem's most clinically advanced therapeutic and Amorcyte is enrolling patients for a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. We also expect to begin a Phase 1 clinical trial by 2012/2013 to investigate AMR-001's utility in arresting the progression of congestive heart failure and the associated comorbidities of that disease. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is engaged in collaboration with Becton-Dickinson that is exploring the earlier stage clinical development of a T-cell therapy for autoimmune conditions. In addition, our pre-clinical assets include our VSELTM Technology platform as well as our MSC (mesenchymal stem cells) product candidate for regenerative medicine.

For more information on NeoStem, please visit http://www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's successful development of cell therapeutics, as well as the future of the cell therapeutics industry. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's periodic filings with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Continue reading here:
NeoStem to Present at the Seventh Annual JMP Securities Healthcare Conference

Posted in Cell Therapy | Comments Off on NeoStem to Present at the Seventh Annual JMP Securities Healthcare Conference

Global Markets for Stem Cells and Stem Cell Products Expected to Reach $6.6 Billion by 2016

Posted: July 10, 2012 at 9:14 pm

DALLAS, July 10, 2012 /PRNewswire/ -- ReportsnReports.com adds a new market research report "Global Markets for Stem Cells" to its store. The highlights of this stem cells report includes:

The aim of this report is to provide detailed market, technology, and industry analyses to help readers quantify and qualify the market for prescription drug products. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2016; these are based on industry sources and considered assessment of the regulatory environment, healthcare policies, demographics, and other factors that directly affect the stem cell-related drug market. The wider economic environment is also taken into account.

The report examines strategies employed by companies specializing in this field to meet the challenges of a competitive and fast-growing market.

SCOPE OF REPORT

This report discusses the implications of stem cell research and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global terms and analyzed by the most important national markets. The important technologies supporting stem cells are reviewed, and the nature and structure of the stem cell industry is discussed with profiles of the leading companies, including recent M&A activity. Five-year sales forecasts are provided for the national markets and the major therapeutic categories of products involved.

MARKET ANALYSES AND FORECASTS

Market figures are based on revenues at the manufacturer level and are projected at 2012-dollar value without attempting to predict the effect of inflation/deflation. Therapeutic categories quantified and forecast include cancer, CNS diseases, infections and cardiovascular. Major country markets in three regionsAmericas, Europe and Asiaare analyzed and forecast, with a summary for the rest of the world.

METHODOLOGY

Visit link:
Global Markets for Stem Cells and Stem Cell Products Expected to Reach $6.6 Billion by 2016

Posted in Stem Cell Videos | Comments Off on Global Markets for Stem Cells and Stem Cell Products Expected to Reach $6.6 Billion by 2016

NeoStem to Present at the Seventh Annual JMP Securities Healthcare Conference

Posted: July 10, 2012 at 3:16 pm

NEW YORK, July 10, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a cell therapy company, today announced that its CEO will present at the Seventh Annual JMP Securities Healthcare Conference on July 12, 2012.

The presentation will be webcast live and available to view at the following web address: http://wsw.com/webcast/jmp18/nbs/. The webcast will be archived for 90 days following the live presentation.

The Seventh Annual JMP Securities Healthcare Conference

About NeoStem, Inc.

NeoStem, Inc. ("we," "NeoStem" or the "Company") continues to develop and build on its core capabilities in cell therapy to capitalize on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a large role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. Our January 2011 acquisition of Progenitor Cell Therapy, LLC ("PCT") provides NeoStem with a foundation in both manufacturing and regulatory affairs expertise. We believe this expertise, coupled with our existing research capabilities and collaborations, will allow us to achieve our mission of becoming a premier cell therapy company. Our PCT subsidiary's manufacturing base is one of the few current Good Manufacturing Practices ("cGMP") facilities available for contracting in the burgeoning cell therapy industry. Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR-001, represents NeoStem's most clinically advanced therapeutic and Amorcyte is enrolling patients for a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. We also expect to begin a Phase 1 clinical trial by 2012/2013 to investigate AMR-001's utility in arresting the progression of congestive heart failure and the associated comorbidities of that disease. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is engaged in collaboration with Becton-Dickinson that is exploring the earlier stage clinical development of a T-cell therapy for autoimmune conditions. In addition, our pre-clinical assets include our VSELTM Technology platform as well as our MSC (mesenchymal stem cells) product candidate for regenerative medicine.

For more information on NeoStem, please visit http://www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's successful development of cell therapeutics, as well as the future of the cell therapeutics industry. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company's periodic filings with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

See the article here:
NeoStem to Present at the Seventh Annual JMP Securities Healthcare Conference

Posted in Cell Therapy | Comments Off on NeoStem to Present at the Seventh Annual JMP Securities Healthcare Conference

New paper stirs more debate about whether adult ovaries can make new eggs | Not Exactly Rocket Science

Posted: July 10, 2012 at 8:14 am

Any study that claims to overturn long-held dogmas is going to run headlong into controversy. Take, for example, a stream of recent papers which apparently showed that adult ovaries contain stem cells capable of producing eggs.

If thats true, its a really big deal. For decades, the textbooks have said that women are born with their lifetime supply of eggs, which slowly dwindle away and are never replaced. If adult ovaries do indeed have stem cells that can regenerate new eggs, that has big implications for fertility treatments, and when a woman could potentially have children.

But wait! A new study, which used a different technique to isolate these ovarian stem cells in mice, found that they dont divide, and never produce actual eggs. Maybe the textbooks are fine as they are?

But WAIT! This study, far more than many of the others I cover, has divided opinion. Obviously, the authors think that it deals a critical blow to the idea of egg-making adult stem cells. And obviously, one of the people behind the stem cell discovery thinks that the new experiments arent very good. I also contacted four other scientists who work on ovarian biology and their views differ considerably.

Ive written about this story for The Scientist so head over there for the details, and the grounds for the disagreement.

Image from RWJMS IVF Laboratory

Originally posted here:
New paper stirs more debate about whether adult ovaries can make new eggs | Not Exactly Rocket Science

Posted in Stem Cell Videos | Comments Off on New paper stirs more debate about whether adult ovaries can make new eggs | Not Exactly Rocket Science

Page 2,698«..1020..2,6972,6982,6992,700..2,7102,720..»